Jump to Main Contents
ncc en
HOME > Publication & Reports > Annual Report 2022 > Center for Cancer Genomics and Advanced Therapeutics

Annual Report 2022

Section of Liaison for Cancer Genomic Medicine Hospitals

Natsuko Okita, Hideki Ueno, Yusuke Okuma, Tatsuya Suzuki

Introduction

 Our mission in this liaison room is to promote the cancer genomic medicine by sharing and solving practical problems of the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) among the staff at Cancer Genomic Medicine Hospitals. Cancer genomic medicine requires enrichment of human resources, systems, know-how in operations, and the realization of different needs of each region. Our aim is to capture and share these needs, issues, or practical know-how, so that cancer genomic medicine is performed in a cooperative and efficient manner, and at the same time ensure safety for patients.

The Team and What We Do

 We periodically hold online meetings with members of the 13 designated core hospitals for Cancer Genomics Medicine nationwide to share issues and discuss solutions.

Future Prospects

 It has been four years since the launch of cancer genome profiling test. The number of cases has reached 60,000, and the environment surrounding cancer treatment is changing with the approval of new panels, expansion of cancer genomic hospitals and replacement of designated hospitals for cancer genomic medicine. We will continue to respond to these changes, continuing to perform the secretariat function of the Clinical Practice Working Group and collaboration among hospitals.